Rocket Pharmaceuticals, Inc. (RCKT) News
Filter RCKT News Items
RCKT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RCKT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RCKT News From Around the Web
Below are the latest news stories about ROCKET PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RCKT as an investment opportunity.
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceCRANBURY, N.J., January 02, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu |
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 “should be an inflection year” for Rocket with multiple clinical and regulatory catalysts “potentially creating strong momentum” with the shares trading near 52-week lows. Rocket’s RP-A501 for Danon disease has potential to be a $1B commercial opportunity, the analyst tells investors in a research note. The firm thinks an accelerated approval pathway may be possibl |
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush SaysRocket Pharmaceuticals' (RCKT) continued pipeline development together with its in-house manufacturi |
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […] |
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'Jefferies initiated a "buy" rating on Rocket Pharmaceuticals, based on the biotech firm's experimental gene therapies. |
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockCRANBURY, N.J., December 11, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offe |
Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockCRANBURY, N.J., December 10, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that it intends to offer and sell $150 million of shares of its common stock in an underwritten public offering. In addition, Rocket intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock |
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx ConferenceCRANBURY, N.J., November 26, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 7th Annual Evercore HealthCONx Conference in Miami, Florida. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 3, at 1:45 p.m. ET and host investor meetings throughou |
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: AnalystOn Monday, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease. Danon disease is a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness), and intellectual disability. Also Read: FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides Danon dise |
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association ConferenceCRANBURY, N.J., November 18, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months (sustained up to 60 months) and reduction of l |